SEED Biosciences completes CHF 1 million Series A financing round
19.11.2020
Life-sciences startup SEED Biosciences raised CHF 1 million in a Series A fundraising round. The capital will support the company’s growth ambitions, product industrialization, and further develop its proprietary technology. The funding round was led by a new tech-savvy investor together with existing business angels from the biotech and lab automation industries. SEED Biosciences also welcomed Chris Radloff as the new Chairman of the Board of Directors.
 SEED Biosciences co-founders Dr. David Bonzon (CTO) and Dr. Georges Muller (CEO)
|
 |
Lausanne-based SEED Biosciences was a Venture Kick winner in 2018 and a Venture Leader Life Sciences in 2017. This recent equity financing raise comes as SEED Biosciences scales to meet strong demand in the single-cell biology field, putting the company on track to reach profitability in 2022.
“Our purpose is to help scientists around the world develop safer and more efficient biotherapies faster and at lower costs. Their success is our success. With this funding, we are doubling our team so as to invest more resources into sales and manufacturing,” said Georges Muller, SEED Biosciences’ CEO and co-founder. “Since launching our first product on the market in April of this year, we have helped many scientists in pharma companies and top-notch research centers to increase their productivity. Using DispenCell, our clients have solved important bottlenecks in workflows such as in single-cell cloning, CRISPR gene-editing, and single-cell omics. This is undoubtedly due to the strength of DispenCell’s technology and data, which guarantee the traceability of the single-cell isolation process as well as the preservation of the most precious cells. With the support of a new private investor, we’re building upon this winning formula in new markets and with new capabilities.”
A new Chairman with a track record in the liquid handling business
CEO Georges Muller also welcomed Chris Radloff as new Chairman of the Board of Directors: “Chris is a senior executive with a successful track record of leading global businesses in the laboratory equipment industry creating value and generating profitable growth. Throughout his career, he collected experience as General Manager/CEO in mid-size private organizations as well as in global public Fortune 500 companies. Currently acting as a board member in several startups, Chris brings to SEED Biosciences its accumulated expertise in developing international markets and driving innovation organically and through partnerships and acquisitions.”
“Our purpose is to help scientists around the world develop safer and more efficient biotherapies faster and at lower costs. Their success is our success. With this funding, we are doubling our team so as to invest more resources into sales and manufacturing,” said Georges Muller, SEED Biosciences’ CEO and co-founder. “Since launching our first product on the market in April of this year, we have helped many scientists in pharma companies and top-notch research centers to increase their productivity. Using DispenCell, our clients have solved important bottlenecks in workflows such as in single-cell cloning, CRISPR gene-editing, and single-cell omics. This is undoubtedly due to the strength of DispenCell’s technology and data, which guarantee the traceability of the single-cell isolation process as well as the preservation of the most precious cells. With the support of a new private investor, we’re building upon this winning formula in new markets and with new capabilities.”A new Chairman with a track record in the liquid handling business
CEO Georges Muller also welcomed Chris Radloff as new Chairman of the Board of Directors: “Chris is a senior executive with a successful track record of leading global businesses in the laboratory equipment industry creating value and generating profitable growth. Throughout his career, he collected experience as General Manager/CEO in mid-size private organizations as well as in global public Fortune 500 companies. Currently acting as a board member in several startups, Chris brings to SEED Biosciences its accumulated expertise in developing international markets and driving innovation organically and through partnerships and acquisitions.”